Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
52 hedge funds and large institutions have $24.5M invested in Enzo Biochem, Inc. in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
6% more funds holding
Funds holding: 49 → 52 (+3)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
46% less capital invested
Capital invested by funds: $45.6M → $24.5M (-$21.1M)
94% less call options, than puts
Call options by funds: $37K | Put options by funds: $588K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$86.9K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$86K |
| 3 |
Belvedere Trading
Chicago,
Illinois
|
+$68.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$55K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
+$41.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$510K |
| 2 |
Renaissance Technologies
New York
|
-$186K |
| 3 |
Bank of New York Mellon
New York
|
-$119K |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
-$112K |
| 5 |
BlackRock
New York
|
-$82.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Goldman Sachs
New York
| – | -$39K | -17,473 | Closed |
|
|
NA
52
NewEdge Advisors
New Orleans,
Louisiana
| – | +$19 | +10 | New |
|
ENZ Hedge Fund Activity: Q4 2022 in Review
52 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q4 2022, worth a combined $24.5M — down 46% from $45.6M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ENZ positions and 3 closed out — a net gain of 5 holders — while 10 added to existing stakes and 13 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $86.9K. The largest seller was Roumell Asset Management, cutting an estimated $510K.
- 52 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q4 2022, up from 49 in Q3 2022.
- Funds reported $24.5M of Enzo Biochem, Inc. stock for Q4 2022, down 46% quarter-over-quarter.
- 8 funds opened new Enzo Biochem, Inc. positions in Q4 2022 and 3 closed out, a net change of +5 holders.
- The largest Enzo Biochem, Inc. buyer in Q4 2022 was Citadel Advisors, an estimated $86.9K added.
- The largest Enzo Biochem, Inc. seller in Q4 2022 was Roumell Asset Management, an estimated $510K sold.
Based on aggregated 13F filings for Q4 2022.